Fabric Genomics Expands Leadership Team in Precision Medicine

OAKLAND, Calif.--(BUSINESS WIRE)-- Fabric Genomics, Inc., a leader in AI-driven precision medicine, today announced that it has appointed Sean Hofherr, PhD, FACMG, as Chief Operating Officer and Clinical Director. An experienced diagnostics leader and board-certified clinical geneticist, Dr. Hofherr brings more than a decade of experience in execution and innovation in large-scale clinical genomics programs in academia and industry to Fabric Genomics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005240/en/

Fabric Genomics, Inc., a leader in AI-driven precision medicine, today announced that it has appointed Sean Hofherr, PhD, FACMG, as Chief Operating Officer and Clinical Director. An experienced diagnostics leader and board-certified clinical geneticist, Dr. Hofherr brings more than a decade of experience in execution and innovation in large-scale clinical genomics programs in academia and industry to Fabric Genomics. (Photo: Business Wire)

“Dr. Hofherr is a well-respected and influential leader in large scale clinical genetic testing and we are thrilled to welcome him to our team” said Martin Reese, PhD, Co-Founder and CEO of Fabric Genomics. “Sean’s unique expertise in scientific innovation and operational execution within diagnostic CLIA laboratory settings will be invaluable to Fabric’s scientific and clinical leadership while we move from being the leading AI-driven bioinformatics software provider to being the premier sample-to-report clinical solution provider. He will streamline our operations as COO, provide key medical input and expand our offerings as Clinical Director.”

Prior to joining Fabric, Dr. Hofherr, served as Chief Scientific Officer of GeneDx. During his tenure, he led the shift to scalable exome and genome testing including rapid offerings for both, setting the path for the testing firm to become the leader in large scale clinical genomics. His background also includes building the Molecular Diagnostics program at Children’s National Hospital in Washington, DC.

“Having worked with many clinical genomics technologies, Fabric truly has the leading platform for analysis and interpretation that enables different types of laboratories to deliver genetic and genomic testing at scale. The needs of embedded hospital laboratories and large genomic centers are quite different and Fabric has proven to be the platform that can enable any lab to incorporate clinical genomic testing,” said Dr. Hofherr. “I am excited to join Fabric at an important inflection point in its growth and to contribute to the mission of democratizing clinical genetic testing.”

Dr. Hofherr completed his clinical training in Molecular and Biochemical Genetics from the Mayo Clinic. He received his PhD from Baylor College of Medicine in Molecular and Human Genetics.

About Fabric Genomics

Fabric Genomics is democratizing genomics-driven precision medicine. The company provides labs with end-to-end solutions that include assay design and validation support, the Fabric Enterprise software platform, and the clinical interpretation services needed to scale genetic testing. The Fabric Enterprise platform includes secondary analysis, tertiary analysis, AI-driven bioinformatics, and clinical reporting tools. At the core of this platform is a suite of sophisticated AI algorithms that turn data into expert clinical insights in a matter of minutes versus days. Fabric Genomics tools have applications across a variety of use cases including oncology and cardiovascular risk screening, cancer tumor profiling, and newborn screening or carrier testing for rare genetic disorders. Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics, and clinical diagnostics. To learn more, visit fabricgenomics.com and follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005240/en/